Amgen Expands Development Plans For Highly Anticipated Obesity Drug

investors.com/news/technology/amgen-obesity-drug-maritide-eli-lilly-zepbound

Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions and sleep apnea.
The post Amgen Expands Development Plans For Highly Anticipated Obesity Drug appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-06-23 18:30:00.
The Entire Business World on a Single Page. Free to Use →